4sc

4SC focuses its efforts on creating new types of small molecule medications that target essential processes in cancer progression, such as histone deacetylases (HDAC). These medications aim to offer patients innovative treatment choices that are more manageable and effective than current therapies, ultimately improving their quality of life. 4SC's current product pipeline consists of two programs undergoing clinical development: resminostat and domatinostat. 4SC aims to advance its proprietary drug development initiatives to enhance the Company's overall value by establishing valuable partnerships with pharmaceutical and biotechnology firms.